DK3426781T3 - Mikro-rna'er og fremgangsmåder til anvendelse deraf - Google Patents

Mikro-rna'er og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3426781T3
DK3426781T3 DK17712348.6T DK17712348T DK3426781T3 DK 3426781 T3 DK3426781 T3 DK 3426781T3 DK 17712348 T DK17712348 T DK 17712348T DK 3426781 T3 DK3426781 T3 DK 3426781T3
Authority
DK
Denmark
Prior art keywords
rnas
micro
methods
Prior art date
Application number
DK17712348.6T
Other languages
Danish (da)
English (en)
Inventor
Anthony D Saleh
Waes Carter Van
Zhong Chen
Hui Cheng
Original Assignee
Us Health
Mirecule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Mirecule Inc filed Critical Us Health
Application granted granted Critical
Publication of DK3426781T3 publication Critical patent/DK3426781T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK17712348.6T 2016-03-07 2017-03-07 Mikro-rna'er og fremgangsmåder til anvendelse deraf DK3426781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662304844P 2016-03-07 2016-03-07
PCT/US2017/021178 WO2017156015A2 (en) 2016-03-07 2017-03-07 Micrornas and methods of their use

Publications (1)

Publication Number Publication Date
DK3426781T3 true DK3426781T3 (da) 2024-09-30

Family

ID=58361152

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17712348.6T DK3426781T3 (da) 2016-03-07 2017-03-07 Mikro-rna'er og fremgangsmåder til anvendelse deraf

Country Status (7)

Country Link
US (2) US11655469B2 (enExample)
EP (1) EP3426781B1 (enExample)
JP (1) JP2019512489A (enExample)
CN (3) CN117757794A (enExample)
DK (1) DK3426781T3 (enExample)
ES (1) ES2986046T3 (enExample)
WO (1) WO2017156015A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492607A3 (en) * 2017-11-30 2019-08-14 Università Degli Studi Di Torino Urinary mirnas for the in vitro diagnosis of bladder cancer
WO2020227604A1 (en) * 2019-05-08 2020-11-12 Nova Southeastern University Regulation of nucleotide excision repair (ner) by microrna for treatment of breast cancer
US20220296629A1 (en) * 2019-06-03 2022-09-22 Carmel Haifa University Economic Corporation Ltd. Human head and neck cancer treatment
CN111235274A (zh) * 2020-01-18 2020-06-05 山西医科大学第一医院 喉鳞癌血清外泌体标志物筛选方法和外泌体来源miR-941应用
EP4127175A4 (en) * 2020-04-02 2025-01-22 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
CN112007043B (zh) * 2020-08-24 2021-07-20 谢琦 抗结直肠癌的药物或组合物
WO2022056454A2 (en) * 2020-09-14 2022-03-17 President And Fellows Of Harvard College Methods and compositions for treating hpv-positive cancers
CN112294960B (zh) * 2020-10-30 2022-02-08 浙江大学 微小分子RNA-30b-5p作为靶分子的用途
CN112359115B (zh) * 2020-11-30 2022-08-30 河北仁博科技有限公司 与肿瘤细胞顺铂耐药性相关的miR-517a-3p及其应用
CN112481273B (zh) * 2020-12-29 2023-11-24 南通大学附属医院 结直肠癌抑癌基因及其启动子区高dna甲基化的验证方法
EP4124656A1 (en) * 2021-07-26 2023-02-01 Martin-Luther-Universität Halle-Wittenberg Pd-l1 micrornas
CN113528669A (zh) * 2021-08-19 2021-10-22 柳州市工人医院 一种利用Small RNA测序技术揭示miRNA对肝癌作用机制的方法
WO2023137528A1 (en) * 2022-01-21 2023-07-27 Griffith University Biomarkers and uses therefor
CN114574596B (zh) * 2022-03-11 2023-06-23 浙江省农业科学院 SNPs分子标记g.43851G＞A及其在湖羊分子标记辅助育种中的应用
CN115161321B (zh) * 2022-06-24 2023-04-18 天津市农业科学院 ssc-miR-30c-3p在制备抗PDCoV增殖药物中的应用
AU2023306304A1 (en) * 2022-07-10 2025-01-09 Precigen, Inc. POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION
CN120731090A (zh) * 2022-12-28 2025-09-30 学校法人自治医科大学 腹膜种植抑制剂、腹膜种植抑制方法、腹膜种植预防方法以及腹膜种植治疗方法
TW202444389A (zh) * 2023-01-30 2024-11-16 中央研究院 藉由調節mir34治療脊髓性肌肉萎縮症(sma)以及mir34作為sma的預測生物標記的用途
EP4417709A1 (en) * 2023-02-14 2024-08-21 Gemeinnützige Salzburger Landeskliniken Betriebsges.mbH Mirna-based diagnostic assay for the detection of a risk to develop skin tumors against the background of severe skin lesions
WO2024197262A1 (en) * 2023-03-23 2024-09-26 Purdue Research Foundation Fully modified mir-34a and related conjugates, compositions and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2465574T3 (es) 2002-05-03 2014-06-06 Duke University Un método para regular la expresión génica
WO2005017145A1 (ja) * 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
WO2006078278A2 (en) 2004-04-27 2006-07-27 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
JP4584987B2 (ja) 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
JP2008504840A (ja) 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US7893034B2 (en) * 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1904111A4 (en) 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
WO2007149521A2 (en) 2006-06-20 2007-12-27 The Johns Hopkins University Nucleotide motifs providing localization elements and methods of use
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2008069940A2 (en) 2006-12-06 2008-06-12 Albert Einstein College Of Medicine Of Yeshiva University Multi-microrna methods and compositions
CN101622350A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
WO2008088858A2 (en) 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
WO2009018492A2 (en) 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
US20090148535A1 (en) * 2007-12-06 2009-06-11 Minerva Biotechnologies Corporation Method for treating cancer using interference rna
CN102112110A (zh) 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
JP2010094122A (ja) * 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
US8729041B2 (en) * 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
SG176716A1 (en) 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
WO2011034811A1 (en) 2009-09-17 2011-03-24 Sigma-Aldrich Co. Short rna mimetics
WO2011103135A1 (en) * 2010-02-16 2011-08-25 University Of Miami The use of mir-30e to treat vascular lesions
CA2799403C (en) * 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
CN105969773A (zh) * 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
GB201102283D0 (en) * 2011-02-09 2011-03-23 Ucl Business Plc Treatment
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
US8846633B2 (en) * 2011-11-07 2014-09-30 Taipei Veterans General Hospital Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microRNA145
WO2014117050A2 (en) * 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
JP6587142B2 (ja) * 2013-02-15 2019-10-09 国立大学法人 東京医科歯科大学 マイクロｒｎａからなるがん治療剤
US9518300B2 (en) * 2014-04-14 2016-12-13 Dana-Farber Cancer Institute, Inc. Composition and method for treating a hematological malignancy
SG10201809290SA (en) * 2014-04-25 2019-01-30 Childrens Medical Ct Corp Compositions and Methods to Treating Hemoglobinopathies

Also Published As

Publication number Publication date
CN109312341B (zh) 2024-02-27
US20190284554A1 (en) 2019-09-19
CN117757795A (zh) 2024-03-26
WO2017156015A2 (en) 2017-09-14
ES2986046T3 (es) 2024-11-08
US11655469B2 (en) 2023-05-23
CN109312341A (zh) 2019-02-05
EP3426781B1 (en) 2024-06-26
US20230295631A1 (en) 2023-09-21
JP2019512489A (ja) 2019-05-16
CN117757794A (zh) 2024-03-26
WO2017156015A3 (en) 2017-10-19
EP3426781A2 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
IL271025A (en) Multibiotic agents and methods of using the same
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3515478T3 (da) Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
DK3429596T3 (da) Cykliske dinukleotide forbindelser og brugs metoder
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK4105223T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3377612T3 (da) Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3310812T3 (da) Anti-HER2-antistoffer og fremgangsmåder til anvendelse
DK3828194T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf